<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129275">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01694576</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-N23-RCT</org_study_id>
    <secondary_id>JSCC-RCT01</secondary_id>
    <nct_id>NCT01694576</nct_id>
  </id_info>
  <brief_title>NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation</brief_title>
  <official_title>Adjuvant Chemotherapy or Not for NPC Patients Staged N2-3M0 After Concurrent Chemotherapy :a Phase Ⅱ Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Cancer Institute &amp; Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      By this clinical trial, the investigators are trying to give an answer to such a question.
      Whether NPC patients staged N2-3M0 need adjuvant chemotherapy consisting of paclitaxel and
      platinum after concurrent chemoradiation?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent research (Lancet Oncology 2012)shows that no survival benefits were achieved by
      adding adjuvant chemotherapy after concurrent chemoradiation in patients with locoregionally
      advanced NPC. But in patients with even high risk of distant metastasis(staged N2-3M0),is
      adjuvant chemotherapy necessary?
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>treatment toxicity based on a CTCAE3.0 grading system</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>progress free survival</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>distant metastasis free survival</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Adjuvant chemotherapy with paclitaxel and nedaplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be followed up without adjuvant chemotherapy after concurrent chemoradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy with paclitaxel and nedaplatin</intervention_name>
    <description>Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation</description>
    <arm_group_label>Adjuvant chemotherapy with paclitaxel and nedaplatin</arm_group_label>
    <other_name>Adjuvant chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. pathologically confirmed untreated NPC patients staged N2-3M0

          2. age: 18y - 65y

          3. with MRI examinations

          4. ECOG≤2

          5. with written consent

        Exclusion Criteria:

          1. without a second cancer

          2. pregnancy

          3. with other severe diseases(blood,liver ,kidney or heart diseases)

          4. could not staged properly

          5. without written consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xia He, M.D. and PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiotherapy,Jiangsu Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianhua Xu, M.D.</last_name>
    <phone>15805161106</phone>
    <email>xu016@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Xu, M.D.</last_name>
      <phone>15805161106</phone>
      <email>xu016@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Jianhua Xu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>September 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jiangsu Cancer Institute &amp; Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Xia He</investigator_full_name>
    <investigator_title>Director of the department of radiotherapy</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma staged N2-3M0</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nedaplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
